Program

Session 1: Novel Strategies for Target Identification and Validation

Chairperson: George D. Demetri, Dana-Farber Cancer Institute, Boston, MA
3:15 p.m.-5:15 p.m.

Systematic functional genomics and cancer target identification and validation
William C. Hahn, Dana-Farber Cancer Institute, Boston, MA

Novel strategies for drug development in oncology
D. Gary Gilliland, Merck & Co., Inc., North Wales, PA

Drugging oncogenic transcription factors
Gregory L. Verdine, Harvard University, Cambridge, MA

Keynote Address

5:15 p.m.-6:00 p.m.

Understanding and managing early-stage cancers
Ronald A. DePinho, Dana-Farber Cancer Institute, Boston, MA

Opening Reception

6:00 p.m.-7:30 p.m.

Session 2: Developing Rational Strategies for Combination Therapy

Chairperson: Jeffrey Settleman, Genentech, Inc., South San Francisco, CA
8:00 a.m.-10:00 a.m.

Modeling drug sensitivity and resistance in human tumor-derived cell lines
Jeffrey Settleman

Predictors of RAS/RAF dependence
David B. Solit, Memorial Sloan-Kettering Cancer Center, New York, NY

Rational integration of HDAC inhibitors into cancer therapy
Pamela N. Munster, University of California, San Francisco, CA

Targeting redundancy in RAS-PI3K signaling in NSCLC
Hayley M. McDaid, Albert Einstein College of Medicine, Bronx, NY

Session 3: Implementing Genomics/Genetics in Day-to-Day Clinical Practice

Chairperson: Joseph R. Nevins, Duke University Medical Center, Durham, NC
10:30 a.m.-12:30 p.m.

Variables for individualizing systemic therapy in patients with lung cancer
Gerold Bepler, Karmanos Cancer Institute, Detroit, MI

Utilization of genomic signatures to guide therapeutic decisions
Joseph R. Nevins

Personalized cancer diagnostics
Christopher L. Corless, Oregon Health & Science University, Portland, OR

Genetic testing for breast and ovarian cancer: From risk assessment to therapeutic targeting
Susan M. Domchek, Abramson Cancer Center of University of Pennsylvania, Philadelphia, PA

Mentoring Lunches for Early-Career Investigators

12:30 p.m.-2:00 p.m.

Session 4: Novel Trial Design and Companion Diagnostics

Chairperson: Roy S. Herbst, UT M. D. Anderson Cancer Center, Houston, TX
2:00 p.m.-4:00 p.m.

Gene-based trial matching
Timothy J. Yeatman, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

Toward personalized therapy for advanced non-small cell lung cancer: The M. D. Anderson BATTLE Programs
Roy S. Herbst

The biomarker roadmap: How to integrate biomarker and compound discovery for early clinical decision making
Pearl S. Huang, Merck & Co., Inc., North Wales, PA

Design of phase III clinical trials for predictive oncology
Richard M. Simon, NCI-DCTD, Bethesda, MD

Oral Presentations from Proffered Abstracts

4:00 p.m.-5:00 p.m.

Genomic discovery of CD44-SLC1A2 gene fusions in gastric cancer
Jiong Tao, National University of Singapore, Singapore

Therapeutic intervention targeting a Hedgehog-dependent barrier to drug delivery in pancreatic cancer
Kenneth P. Olive, Columbia University, New York, NY

Preclinical and molecular profiling data suggest LumB breast cancer as a potential indication for co-targeting IGF1R and mTOR with MK-0646 and MK-8669
Theresa Zhang, Merck & Co., Inc., Boston, MA

Integrative analysis of genomic and pharmacologic data from the Cancer Cell Line Encyclopedia
Nicolas Stransky, The Broad Institute, Cambridge, MA

Poster Session A

5:00 p.m.-7:00 p.m.

Session 5: New Models for Cancer and Cancer Biology

Chairperson: M. Celeste Simon, Abramson Cancer Center of University of Pennsylvania, Philadelphia, PA
8:00 a.m.-10:00 a.m.

Spontaneous cancer in dogs: Opportunities for preclinical investigation of novel therapeutics
Cheryl A. London, Ohio State University, Columbus, OH

Evolutionary games in cancer therapy
Robert A. Gatenby, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

Modeling cancer medicine
David A. Tuveson, Cancer Research UK, Cambridge, United Kingdom

HIFs, hypoxia, and tumor progression
M. Celeste Simon

Session 6: New Indications for Old Drugs

Chairperson: Joe W. Gray, Lawrence Berkeley National Laboratory, Berkeley, CA
10:30 a.m.-12:30 p.m.

The evolution of folate analogs: Drugs targeted to folate transporters, drugs targeted to novel enzyme sites, effects on signaling pathways
I. David Goldman, Albert Einstein Cancer Center, Bronx, NY

Altered nutrient requirements in cells with activated mTOR complex 1
John Blenis, Harvard Medical School, Boston, MA

Genomic approaches to drug discovery
Kimberly Stegmaier, Dana-Farber Cancer Institute, Boston, MA

Molecular determinants of response in breast cancer using an in vitro system
Joe W. Gray

Mentoring Lunches for Early-Career Investigators

12:30 p.m.-2:00 p.m.

Session 7: Integration of Cancer Omics Data

Chairperson: Lynda Chin, Dana-Farber Cancer Institute, Boston, MA
2:00 p.m.-4:00 p.m.

Mechanisms of resistance to targeted therapeutics in melanoma
Levi A. Garraway, Dana-Farber Cancer Institute, Boston, MA

Functionalizing the cancer genome
Lynda Chin

The Cancer Genome Atlas: An integrated genomic analysis identifies clinically relevant subtypes of glioblastoma
David N. Hayes, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC

Developing an approach to personalized cancer care: The vision, the challenges, and the obligations
William S. Dalton, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

Poster Session B

4:00 p.m.-6:00 p.m.

Session 8: Invasion and Circulating Tumor Cells

Chairperson: William S. Dalton, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
8:00 a.m.-9:30 a.m.

Identification of subpopulations of circulating tumor cells by single cell molecular analyses
Stefanie S. Jeffrey, Stanford University School of Medicine, Stanford, CA

Pancreatic cancer stem cells and metastasis
William H. Matsui, Johns Hopkins School of Medicine, Baltimore, MD

Molecular characterization of circulating tumor cells
Shyamala Maheswaran, Massachusetts General Hospital, Charlestown, MA

Oral Presentations from Proffered Abstracts

9:30 a.m.-10:00 a.m.

Prediction of survival in diffuse large B-cell lymphoma based on the expression of two genes integrating tumor and microenvironment
Andrew J. Gentles, Stanford University, Stanford, CA

Resistance to EGFR inhibition via the emergence of EGFRvIII-independent tumor growth-promoting mechanisms in glioblastoma
Jill E. Wykosky, Ludwig Institute for Cancer Research, La Jolla, CA

Session 9: Elucidating Drug Resistance in Cancer Drug Development

Chairperson: George D. Demetri, Dana-Farber Cancer Institute, Boston, MA
10:30 a.m.-12:30 p.m.

Is Taxol resistance related to tubulin isotypes?
Cristiano Ferlini, Danbury Hospital, Danbury, CT

Emergence of polyclonal resistance in GIST under selection pressure of kinase inhibitors: Therapeutic challenges to meet with new technology
George D. Demetri

Insights into the biology of EGFR T790M-mediated resistance to EGFR TKIs in lung cancer
William Pao, Vanderbilt University, Nashville, TN

Departure